Patents by Inventor Tomohiro Okawa

Tomohiro Okawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors
    Patent number: 11795172
    Abstract: The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: October 24, 2023
    Assignee: Cardurion Pharmaceuticals, Inc.
    Inventors: Nobuyuki Matsunaga, Junya Shirai, Tomohiro Okawa, Yasufumi Miyamoto, Zenyu Shiokawa, Takashi Nakahata, Akito Shibuya, Akira Kawada, Malcolm MacCoss
  • AMINOPYRIMIDINE COMPOUND
    Publication number: 20220112184
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: April 14, 2022
    Inventors: Nobuyuki MATSUNAGA, Yasufumi MIYAMOTO, Junya SHIRAI, Takashi NAKAHATA, Zenyu SHIOKAWA, Tomohiro OKAWA, Akito SHIBUYA, Malcolm MACCOSS
  • FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS
    Publication number: 20220098207
    Abstract: The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: March 31, 2022
    Inventors: Nobuyuki MATSUNAGA, Junya SHIRAI, Tomohiro OKAWA, Yasufumi MIYAMOTO, Zenyu SHIOKAWA, Takashi NAKAHATA, Akito SHIBUYA, Akira KAWADA, Malcolm MACCOSS
  • HETEROCYCLIC COMPOUND
    Publication number: 20220098180
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: January 29, 2020
    Publication date: March 31, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro ITO, Takeshi YAMAMOTO, Keiko KAKEGAWA, Hideyuki SUGIYAMA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Osamu KUBO, Akinori TOITA, Takuto KOJIMA, Fumiaki KIKUCHI, Minoru SASAKI, Misaki HOMMA, Yasuhiro IMAEDA, Hironobu MAEZAKI, Shiinobu SASAKI, Ayumu SATO, Hirotaka KAMITANI, Yasutomi ASANO, Hironori KOKUBO, Masato YOSHIKAWA
  • Heterocyclic compound
    Patent number: 11274101
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 15, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Makoto Kamata, Hideyuki Sugiyama, Minoru Nakamura, Masataka Murakami, Shuhei Ikeda, Tomohiro Okawa, Hidekazu Tokuhara
  • Heterocyclic compound
    Patent number: 11242348
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: February 8, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Makoto Kamata, Hideyuki Sugiyama, Minoru Nakamura, Masataka Murakami, Shuhei Ikeda, Tomohiro Okawa, Hidekazu Tokuhara
  • Heterocyclic compound
    Patent number: 11236099
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: February 1, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
  • HETEROCYCLIC COMPOUND
    Publication number: 20220017530
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 15, 2021
    Publication date: January 20, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
  • Substituted amines for treating cardiac diseases
    Patent number: 11197858
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: December 14, 2021
    Assignee: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
  • Pyrazoloquinazolinone antitumor agents
    Patent number: 11192893
    Abstract: Compounds of formula: are useful as antitumor agents. In these compounds, R10 is (a) (C1-C10) hydrocarbyl, (C1-C10)halohydrocarbyl, (C1-C6)hydroxyalkyl, or or R10 is (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: December 7, 2021
    Assignee: The Rockefeller University
    Inventors: Tarun M. Kapoor, Moriteru Asano, Kazuyoshi Aso, Michael A. Foley, Yoshiyuki Fukase, Hideki Furukawa, Yashuhiro Hirata, Sachie Takashima, Tomohiro Okawa, Yuta Tanaka, Yayoi Yoshitomi
  • Aromatic compound
    Patent number: 11186565
    Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: November 30, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Seiji Miwatashi, Yasufumi Miyamoto, Koji Watanabe, Yayoi Nakayama, Yuko Hitomi, Jumpei Aida, Nobuyuki Takakura, Hideki Furukawa, Naoyoshi Noguchi, Yasuhiro Hirata, Kazuaki Takami, Norihito Tokunaga, Tomohiro Okawa, Akito Shibuya, Shizuo Kasai, Toshitake Kobayashi, Tsuyoshi Maekawa
  • Aminopyrimidine compound
    Patent number: 11130752
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 28, 2021
    Assignee: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki Matsunaga, Yasufumi Miyamoto, Junya Shirai, Takashi Nakahata, Zenyu Shiokawa, Tomohiro Okawa, Akito Shibuya, Malcolm MacCoss
  • HETEROCYCLIC COMPOUND
    Publication number: 20210139491
    Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: June 19, 2018
    Publication date: May 13, 2021
    Inventors: Kazuaki TAKAMI, Masaki SETO, Shinobu SASAKI, Haruhi ANDO, Masaki OGINO, Tomoko OHASHI, Toshihiro IMAEDA, Ikuo FUJIMORI, Yasuhiro TSUKIMI, Masami YAMADA, Kenichiro SHIMOKAWA, Takeshi WAKABAYASHI, Masataka MURAKAMI, Makoto FUSHIMI, Tomohiro OKAWA, Jinichi YONEMORI, Tomohiro OHASHI, Hideo SUZUKI, Hironobu MAEZAKI, Ayumu SATO, Yasutomi ASANO, Steve SWANN
  • HETEROCYCLIC COMPOUND
    Publication number: 20200255439
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: September 27, 2018
    Publication date: August 13, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Makoto KAMATA, Hideyuki SUGIYAMA, Minoru NAKAMURA, Masataka MURAKAMI, Shuhei IKEDA, Tomohiro OKAWA, Hidekazu TOKUHARA
  • SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES
    Publication number: 20200230137
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 23, 2020
    Applicant: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA
  • PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS
    Publication number: 20200148687
    Abstract: Compounds of formula: are useful as antitumor agents. In these compounds, R10 is (a) (C1-C10) hydrocarbyl, (C1-C10)halohydrocarbyl, (C1-C6)hydroxyalkyl, or or R10 is (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.
    Type: Application
    Filed: May 18, 2018
    Publication date: May 14, 2020
    Applicant: The Rockefeller University
    Inventors: Tarun M. KAPOOR, Moriteru ASANO, Kazuyoshi ASO, Michael A. FOLEY, Yoshiyuki FUKASE, Hideki FURUKAWA, Yashuhiro HIRATA, Sachie TAKASHIMA, Tomohiro OKAWA, Yuta TANAKA, Yayoi YOSHITOMI
  • Heterocyclic compound
    Patent number: 10610520
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 7, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuhei Ikeda, Hideyuki Sugiyama, Jumpei Aida, Hidekazu Tokuhara, Tomohiro Okawa, Yuya Oguro, Minoru Nakamura, Masataka Murakami
  • AMINOPYRIMIDINE COMPOUND
    Publication number: 20200095240
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: September 24, 2019
    Publication date: March 26, 2020
    Inventors: Nobuyuki MATSUNAGA, Yasufumi MIYAMOTO, Junya SHIRAI, Takashi NAKAHATA, Zenyu SHIOKAWA, Tomohiro OKAWA, Akito SHIBUYA, Malcolm MacCoss
  • AROMATIC COMPOUND
    Publication number: 20200039957
    Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
    Type: Application
    Filed: March 29, 2018
    Publication date: February 6, 2020
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Seiji MIWATASHI, Yasufumi MIYAMOTO, Koji WATANABE, Yayoi NAKAYAMA, Yuko HITOMI, Jumpei AIDA, Nobuyuki TAKAKURA, Hideki FURUKAWA, Naoyoshi NOGUCHI, Yasuhiro HIRATA, Kazuaki TAKAMI, Norihito TOKUNAGA, Tomohiro OKAWA, Akita SHIBUYA, Shizuo KASAl, Toshitake KOBAYASHI, Tsuyoshi MAEKAWA
  • Substituted amines for treating cardiac diseases
    Patent number: 10543212
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: January 28, 2020
    Assignee: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya